Back to results
US 2022/0024930 A1Published application
Ion channel modulators
AssigneePraxis Precision Medicines, Inc.
InventorsAndrew Mark Griffin, Brian Edward Marron, Gabriel Martinez Botella
Life of this patent
Estimating the term…
Abstract
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
Claims23
1-115. (canceled)
A compound having the Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein
- X and Y are each independently CRd or N;
- R1 is
- monocyclic C3-6 cycloalkyl, or 4- to 7-membered monocyclic heterocyclyl, wherein said cycloalkyl and heterocyclyl are optionally substituted with one or more Ra;
- R2 is C1-4haloalkyl, phenyl, or monocyclic C3-6 cycloalkyl optionally substituted with one or more Rb;
- R3 is hydrogen, C1-4alkyl, or C1-4haloalkyl;
- R4 is hydrogen or C1-4alkyl;
- R5 is halo;
- R6 is C1-4alkyl or C1-4haloalkyl, wherein said C1-4alkyl or C1-4haloalkyl are each substituted with ORc;
- t is 0, 1, or 2;
- Ra and Rb are each independently selected from is selected from halo, C1-4alkyl, Ci-4haloalkyl, C1-4alkoxy, and C1-4haloalkoxy,
- Rc is C1-4alkyl optionally substituted with C3-6 cycloalkyl or C1-4alkoxy, or C3-6 cycloalkyl;
- and
- Rd is hydrogen or C1-4alkyl;
- provided the compound is not:
- or a pharmaceutically acceptable salt thereof.
13 more elements
Dependencies are inferred from the claim text.